LoQus23 Therapeutics Ltd
Treating neurodegenerative diseases such as Huntington’s and other triplet repeat expansion diseases
15 employees · est. 2019 · Cambridge, United Kingdom
Side-by-Side Comparison
| Metric | LoQus23 Therapeutics Ltd | Renasant Bio |
|---|---|---|
| Founded | ||
| Founded | 2019 | Not tracked yet |
| Headquarters | ||
| Headquarters | Cambridge, United Kingdom | Berkeley, United States |
| Employees | ||
| Employees | 15 | 33 |
| Industry | ||
| Industry | Biotechnology, Pharmaceutical | Biotechnology |
| Funding Stage | ||
| Funding Stage | Series A | Seed |
| Total Funding | ||
| Total Funding | $46.50M | $54.50M |
| Funding Rounds | ||
| Funding Rounds | 3 | 1 |
| Services | ||
| Services | Development of somatic expansion inhibitors, Research on neurodegenerative diseases | Development of small molecule correctors and potentiators, Restoration of PC1/2 protein function, Disease-modifying therapy development for ADPKD |
| Target Customers | ||
| Target Customers | Patients with Huntington's Disease, Individuals with triplet repeat expansion diseases, Healthcare providers, Pharmaceutical companies | Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD), Biopharma researchers, Healthcare providers specializing in renal diseases |
| Taxonomy | ||
| Taxonomy | DNA Instability, Neurodegenerative Disease, Small Molecule Therapies, Aberrant DNA Mismatch Repair, Huntington’s Disease, Triplet Repeat Diseases, DDF-formed Company, DNA Damage Repair Pathways, Pharmaceuticals | Biopharmaceutical, ADPKD Treatment, Disease-Modifying Therapies, Oral Small Molecules, Genetic Disease, End-Stage Renal Failure, Protein Function Restoration, Drug Development, Polycystic Kidney Disease, Biomedical Innovation, Small Molecule Correctors, Small Molecule Potentiators |
| Website | ||
| Website | loqus23.com | renasantbio.com |
About LoQus23 Therapeutics Ltd
LoQus23 Therapeutics Ltd, founded in 2019, is a biotechnology company based in the United Kingdom that focuses on combating neurodegenerative diseases. With the slogan "Stopping DNA instability; Slowing neurodegenerative disease," LoQus23 is committed to the discovery of oral small molecule therapie...
About Renasant Bio
Renasant Bio, with its slogan "Transforming the Treatment of ADPKD," is making significant strides in the Biotechnology sector. The company is dedicated to developing disease-modifying oral small molecule treatments specifically for autosomal dominant polycystic kidney disease (ADPKD), a leading gen...
We will tell you when either one moves
BounceWatch watches LoQus23 Therapeutics Ltd and Renasant Bio for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at LoQus23 Therapeutics L... and Renasant Bio — by email.
Frequently Asked Questions
Compare LoQus23 Therapeutics Ltd with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at LoQus23 Therapeutics Ltd on 11 Sep 2024, and Renasant Bio on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
